Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 AGTC-401 gene therapy study for CNGB3-associated congenital achromatopsia
MOH_2020-02-13_008699Phase 2Not yet recruiting
- Sponsor
- Applied Genetic Technologies Corporation
- Start
- Oct 2019
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AGTC-401 in achromatopsia (ACHM), sponsored by Applied Genetic Technologies Corporation. Primary endpoint: Safety and tolerability of AGTC-401. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
AGTC-401
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on MOH_2020-02-13_008699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-13_008699.